Alexion Filed Motion to Dismiss Antitrust Suit
The drug maker argues the insurer lacks legal standing in a dispute over alleged patent-related market delays.
Updated on Sept. 21, 2026 in Healthcare
Alexion Pharmaceuticals has filed a reply in support of its motion for judgment on the pleadings in an ongoing antitrust lawsuit. The case centers on allegations that the company improperly delayed biosimilar competition for Soliris, a treatment for rare blood and immune disorders.
Why it matters
The dispute centers on whether EmblemHealth has the standing to pursue sham litigation claims based on alleged fraud on the Patent and Trademark Office. This case carries implications for how insurers and manufacturers navigate litigation over pharmaceutical patent strategies and market access.
This filing follows previous judicial findings that specific fraud-on-the-patent-office allegations were insufficiently linked to the insurer's reported injuries. The outcome will determine if the broader antitrust claims proceed to further discovery or are dismissed.
The players
Alexion Pharmaceuticals
A biopharmaceutical company focused on developing therapies for rare blood and immune disorders.
EmblemHealth
A large non-profit health insurance provider managing coverage and drug costs for policyholders.
The details
Alexion Pharmaceuticals maintains that EmblemHealth cannot establish the legal standing necessary to assert its sham litigation claims. The insurer previously argued that the drug maker employed fraud to delay competition, but the court has already narrowed the scope by ruling that certain fraud allegations were too removed from the insurer's actual injuries. This current motion seeks to resolve the remaining claims by arguing that the legal threshold for anticompetitive harm has not been met.
Timeline
September 21, 2026: Alexion Pharmaceuticals filed its reply in support of its motion for judgment on the pleadings.
Market Landscape
This litigation follows the established pattern set by Walker Process cases where courts must determine if patent-related conduct crosses into actionable anticompetitive behavior. It highlights the ongoing tension between intellectual property protections and insurer efforts to reduce drug costs.
Operators in the pharmaceutical and insurance sectors should monitor how the court interprets standing requirements for third-party payors in patent-related antitrust suits. This ruling will clarify whether insurers can successfully challenge manufacturer patent strategies through litigation.
The takeaway
The court's decision will signal the viability of future sham litigation claims brought by insurers against drug developers. Businesses should review their own patent protection compliance and monitor court dockets for developments regarding standing in pharmaceutical antitrust cases.
Further reading
For broader analysis on industry patent disputes, visit the Healthcare section.
